Senolytic

Cepham Introduces Senolytics Inspired by Ayurveda and TCM for Sustainable Aging

Retrieved on: 
Tuesday, February 20, 2024
Ageing, Regeneration, Inflammation, Senolytic, Neuroprotection, Human, Overalls, Traditional Chinese medicine, Cell, Rasayana, Health, Safety, TCM, Notifiable disease, Longevity, Science, Autophagy, Research, DNA, Pharmaceutical industry

SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.

Key Points: 
  • SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.
  • “Cepham’s decision to include senolytics in its Sustainable Aging ingredient offerings reflects our company's commitment to delivering affordable, high-quality, evidence-based, and safe ingredients to customers,” says Christopher Lamb , vice president of commercial strategy at Cepham.
  • The expansion of senolytics in Cepham’s Sustainable Aging product line marks a pivotal moment in the evolution of longevity solutions.
  • For more information about Cepham, Inc. and its Sustainable Aging Product line, please visit https://cepham.com .

Neurohacker Collective Announces Free Masterclass For Health Practitioners On Latest Aging Discovery

Retrieved on: 
Tuesday, January 2, 2024
Research, Clinical trial, Ageing, Scripps Research, Patient, Science, Learning, Mayo Clinic, Senolytic, Master class, Life, Pharmaceutical industry

CARLSBAD, Calif., Jan. 2, 2024 /PRNewswire/ -- Neurohacker Collective, a global nutraceutical company dedicated to healthy aging, has announced a physician's only masterclass about the emerging science of senolytics and how health practitioners can use senolytics in their practice.

Key Points: 
  • CARLSBAD, Calif., Jan. 2, 2024 /PRNewswire/ -- Neurohacker Collective, a global nutraceutical company dedicated to healthy aging, has announced a physician's only masterclass about the emerging science of senolytics and how health practitioners can use senolytics in their practice.
  • The Masterclass on the science of senolytics will be hosted by Neurohacker's Dr. Gregory Kelly, and Dr. Nick Bitz.
  • Neurohacker's science team recently achieved promising results in a double-blind, placebo controlled trial of their health formula for better aging, Qualia Senolytic.
  • Now, their science team is paying their formulation knowledge forward by hosting a free masterclass for other doctors and health professionals.

New drug class prevents key ageing mechanism in organ transplants

Retrieved on: 
Sunday, September 17, 2023
Mayo, Human, Brigham and Women's Hospital, Research, Organ transplantation, Harvard Medical School, Transplant, Congress, Lymph, Deficit spending, Mouse, Physical fitness, Dasatinib, Hospital, Clinical professor, European Society for Primary Immunodeficiencies, Vaccine, Dentistry, Quercetin, Senolytic

ATHENS, Greece, Sept. 18, 2023 /PRNewswire/ -- A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of ageing, in recipients of older donor organs.

Key Points: 
  • ATHENS, Greece, Sept. 18, 2023 /PRNewswire/ -- A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of ageing, in recipients of older donor organs.
  • The pioneering research, presented today at the European Society for Organ Transplantation (ESOT) Congress 2023, opens promising avenues for expanding the organ donor pool and enhancing patient outcomes.
  • By transplanting older donor organs into younger recipients, researchers from Harvard Medical School and the Mayo Clinic investigated the role of transplantation in inducing senescence, a biological mechanism linked to ageing and age-related diseases.
  • The researchers conducted age-disparate heart transplants from both young (3 months) and old (18–21 months) mice into younger recipients.

New drug class prevents key ageing mechanism in organ transplants

Retrieved on: 
Sunday, September 17, 2023
Mayo, Human, Brigham and Women's Hospital, Research, Organ transplantation, Harvard Medical School, Transplant, Congress, Lymph, Deficit spending, Mouse, Physical fitness, Dasatinib, Hospital, Clinical professor, European Society for Primary Immunodeficiencies, Vaccine, Dentistry, Quercetin, Senolytic

ATHENS, Greece, Sept. 18, 2023 /PRNewswire/ -- A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of ageing, in recipients of older donor organs.

Key Points: 
  • ATHENS, Greece, Sept. 18, 2023 /PRNewswire/ -- A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of ageing, in recipients of older donor organs.
  • The pioneering research, presented today at the European Society for Organ Transplantation (ESOT) Congress 2023, opens promising avenues for expanding the organ donor pool and enhancing patient outcomes.
  • By transplanting older donor organs into younger recipients, researchers from Harvard Medical School and the Mayo Clinic investigated the role of transplantation in inducing senescence, a biological mechanism linked to ageing and age-related diseases.
  • The researchers conducted age-disparate heart transplants from both young (3 months) and old (18–21 months) mice into younger recipients.

AI finds drugs that could fight ageing and age-related diseases

Retrieved on: 
Thursday, July 6, 2023
Quercetin, Technology, Osteoarthritis, DNA, Human, University, Spanish National Research Council, Dasatinib, Cancer, Intelligence, COVID, Cell, Pulmonary fibrosis, UV, Machine learning, AI, Senolytic, Vaccine, Pharmaceutical industry, Phosphorus

My colleagues and I recently used this technology to find three promising candidates for senolytic drugs – drugs that slow ageing and prevent age-related diseases.

Key Points: 
  • My colleagues and I recently used this technology to find three promising candidates for senolytic drugs – drugs that slow ageing and prevent age-related diseases.
  • These are cells that are “alive” (metabolically active), but which can no longer replicate, hence their nickname: zombie cells.
  • Elevated numbers of senescent cells have been implicated in a range of diseases, including type 2 diabetes, COVID, pulmonary fibrosis, osteoarthritis and cancer.
  • Given enough high-quality data, AI models can accelerate the amazing work that chemists and biologists do to find treatments and cures for diseases – especially those of unmet need.

Artificial intelligence identifies anti-aging drug candidates targeting ‘zombie’ cells

Retrieved on: 
Thursday, May 4, 2023
Health, Biotechnology, Biomedical engineering, Nobel Prize, Nobel Prize in Chemistry, Institute for Medical Engineering and Science, Human, Broad Institute, McMillan, Nature, Hemolysis, Diabetes, Cardiovascular disease, Ageing, Cancer, Intelligence, Multimedia, Research, Medicine, MIT, Inflammation, Cell, Harvard University, Massachusetts Institute of Technology, Fibrosis, Biology, Machine learning, Apoptosis, Bâtiment des Forces motrices, Drug discovery, Conscience, Mouse, Artificial intelligence, AI, Longevity, Notifiable disease, Princeton University, Synthetic biology, Senolytic, Pharmaceutical industry, Science, List of Nature Research journals, Chemistry

View the full release here: https://www.businesswire.com/news/home/20230504005270/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230504005270/en/
    Senolytics are an emerging class of investigational drug compounds that selectively kill aging-associated senescent cells (left, with red stain) without affecting other cells (right).
  • Using artificial intelligence, researchers from Integrated Biosciences have, for the first time, identified three senolytics with comparable efficacy and superior drug-like properties relative to leading investigational compounds.
  • (Photo: Business Wire)
    “This research result is a significant milestone for both longevity research and the application of artificial intelligence to drug discovery,” said Felix Wong, Ph.D., co-founder of Integrated Biosciences and first author of the publication.
  • Integrated Biosciences was founded in 2022 to overcome these obstacles, target other neglected hallmarks of aging, and advance anti-aging drug development more generally using artificial intelligence, synthetic biology and other next-generation tools.

Qualia Senolytic, Breakthrough Product That Promotes Senescent Cell Elimination, Sells Out In Weeks

Retrieved on: 
Tuesday, August 16, 2022
Polyphenol, Multimedia, Food, Food and Drug Administration, Sleep, Tissue, Research, Herbal, Quality of life, Cell, Fisetin, Senolytic, Skin, Ageing, Human body, Longevity, Health, Disease, Management, Dietary supplement, Pharmaceutical industry

Breakthrough Product To Support Better Aging, Qualia Senolytic, Sells Out Weeks After Launch

Key Points: 
  • Breakthrough Product To Support Better Aging, Qualia Senolytic, Sells Out Weeks After Launch
    "Senolytic research is just starting to get media attention.
  • "We knew Qualia Senolytic offered a breakthrough to the market by aggressively promoting senescent cell elimination.
  • *
    The formulation of Qualia Senolytic was led by naturopathic physician and Neurohacker's Senior Director Of Product Development, Dr. Gregory Kelly.
  • By promoting senescent cell elimination, Qualia Senolytic helps resist aging at the cellular level by supporting tissue rejuvenation and overall physical function.

Newly Discovered Aging Science Goes Mainstream With Qualia Senolytic

Retrieved on: 
Thursday, June 16, 2022
Doctor of Philosophy, Skin, Science, Ageing, Dietary supplement, Research, Alternative, Disease, MD, Senolytic, Quality of life, Sleep, Food, Patient, Longevity, Multimedia, Awareness, Cell, Food and Drug Administration, SAN, Management, Pharmaceutical industry

This class of ingredients became known as "senolytics", whose rough Latin translation is "destroying the old", as in aging cells.

Key Points: 
  • This class of ingredients became known as "senolytics", whose rough Latin translation is "destroying the old", as in aging cells.
  • We're excited to offer a great product on the leading edge of senolytic support becoming an emphasis of supplementation for better aging."
  • "The ingredients in Qualia Senolytic are the ideal therapeutic amounts for my patients", states MD and integrative medicine author Dr. Hyla Cass.
  • "*
    Qualia Senolytic became available throughout North America, Europe, Australia and New Zealand on June 7th.

Global Senolytic Drugs Market Analysis/Research Report 2022: Focus on FOXO4-related Peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022
Health, Pharmaceutical, B cell, Longevity, Ageing, Cataract, Market share, AgeX Therapeutics, Therapy, Cell, Neurodegeneration, Human, Neoplasm, Glaucoma, Degenerative disease, Ministry of Social Affairs, Globe, Growth, Application, Cancer, Senolytic, Fine chemical, Pharmaceutical industry, Dietary supplement

Advances in pharmaceutical drugs and the increasing need for healthy lifespan are accelerating the growth of the global senolytic drugs market.

Key Points: 
  • Advances in pharmaceutical drugs and the increasing need for healthy lifespan are accelerating the growth of the global senolytic drugs market.
  • Thus, the increasing geriatric population across the globe is anticipated to propel the growth of the global senolytic drugs market.
  • Accelerating demand for improving and optimizing personalized and preventive care is further driving the growth of the global senolytic drugs market.
  • To classify and forecast global senolytic drugs market based on type, application, distribution channel, region, and competitive Landscape
    To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc, in global senolytic drugs market

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

Retrieved on: 
Thursday, July 29, 2021
Cancer research, Branches of biology, Apoptosis, Bcl-xL, Mitochondria, Senolytic, Targeted therapy, Medicine, Health sciences

UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma for the clinical development targeting age-related diseases.

Key Points: 
  • UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma for the clinical development targeting age-related diseases.
  • According to the terms of the licensing agreement previously entered into between Ascentage Pharma and UNITY, this progress in clinical development will qualify Ascentage Pharma for a milestone payment in the amount of US$2 million, which will be paid in UNITY common stock.
  • UBX1325 is a small-molecule inhibitor of Bcl-xL, and the first senolytic therapeutic clinically evaluated in an ophthalmological setting.
  • "The continued progress in the clinical development of UBX1325 demonstrated Ascentage Pharma's capabilities in the research and development of apoptosis-targeted therapies," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma.